Mississippi House Bill HB1181

Mississippi 2026 Regular Session

• Introduced: 1/19/26
• Refer: 1/19/26
• Failed: 2/3/26

Caption

AN ACT TO REQUIRE THE ATTORNEY GENERAL TO COMMENCE AN INVESTIGATION INTO THE ACTIVITIES OF PHARMACEUTICAL COMPANIES IN MISSISSIPPI RELATING TO THE DEVELOPMENT, PROMOTION AND DISTRIBUTION OF VACCINES PURPORTED TO PREVENT COVID-19 INFECTION, SYMPTOMS AND TRANSMISSION; TO DECLARE CERTAIN FINDINGS; TO SPECIFY CERTAIN CRIMINAL OFFENSES THAT MUST BE INCLUDED IN THE SCOPE OF THE INVESTIGATION; TO REQUIRE THE ATTORNEY GENERAL TO SUBMIT A STATUS REPORT TO THE LEGISLATURE BEFORE JANUARY 1 OF EACH YEAR THAT THE INVESTIGATION IS ONGOING, WHICH REPORT MAY NOT INCLUDE INFORMATION THAT IS CONFIDENTIAL OR POTENTIALLY THREATENING TO THE INTEGRITY OF THE INVESTIGATION; AND FOR RELATED PURPOSES.

Impact

If passed, HB 1181 would lead to a thorough investigation to identify potential violations comprising deceptive practices affecting trade, business, and professional conduct, as well as specific offenses under the state's criminal statutes. This includes misleading advertising and could extend to more serious accusations involving fraud and conspiratorial charges that relate to the pharmaceutical industry's dealings. The findings from this inquiry could lead to significant legal repercussions for those found culpable of misconduct.

Summary

House Bill 1181 mandates the Mississippi Attorney General to initiate an investigation into the practices of pharmaceutical companies regarding the development, promotion, and distribution of COVID-19 vaccines. The bill expresses concerns about the truthfulness of claims made by these companies regarding vaccine effectiveness and safety, especially given the circumstances under which many citizens were required to be vaccinated. It highlights the importance of truthful representations in maintaining public health and trust in pharmaceutical communications.

Reporting

Under the bill, the Attorney General is required to provide annual status updates to the legislature on the investigation's progress. These reports will omit any sensitive information that could compromise the investigation's integrity. The act takes effect on July 1, 2026, providing office time for the necessary planning and initiation of the investigation.

Contention

The proposal may provoke contention regarding its implications for pharmaceutical companies and public health policies. Proponents argue that the legislation is necessary to hold these companies accountable for their messaging and practices, which they believe could endanger public welfare. Critics, however, may see this as an overreach that could disrupt the pharmaceutical market and hinder access to essential health provisions. There is a risk that such scrutiny could lead to public distrust in not only the COVID-19 vaccines but also in broader vaccine and public health initiatives.